share_log

Teladoc Health | 144: Notice of proposed sale of securities pursuant to Rule 144

Teladoc Health | 144: Notice of proposed sale of securities pursuant to Rule 144

Teladoc Health | 144:拟议出售证券
美股sec公告 ·  04/19 15:55
Moomoo AI 已提取核心信息
Jason N. Gorevic, a former officer and director of Teladoc Health, Inc., is set to sell 88,854 common shares of the company on April 19, 2024. The shares, which are expected to be sold for an aggregate market value of approximately $1,153,982.45, were acquired by Gorevic on April 18, 2024, as part of a restricted stock vesting and are considered compensation from the issuer. This transaction follows a previous sale of 53,755 common shares by Gorevic in the past three months, which had gross proceeds of $780,286.09.
Jason N. Gorevic, a former officer and director of Teladoc Health, Inc., is set to sell 88,854 common shares of the company on April 19, 2024. The shares, which are expected to be sold for an aggregate market value of approximately $1,153,982.45, were acquired by Gorevic on April 18, 2024, as part of a restricted stock vesting and are considered compensation from the issuer. This transaction follows a previous sale of 53,755 common shares by Gorevic in the past three months, which had gross proceeds of $780,286.09.
Teladoc Health, Inc. 前高管兼董事杰森·戈雷维奇定于2024年4月19日出售该公司的88,854股普通股。这些股票预计将以约1,153,982.45美元的总市值出售,作为限制性股票归属的一部分,于2024年4月18日被戈雷维奇收购,被视为发行人的补偿。该交易是在戈雷维奇在过去三个月中出售了53,755股普通股之后进行的,总收益为780,286.09美元。
Teladoc Health, Inc. 前高管兼董事杰森·戈雷维奇定于2024年4月19日出售该公司的88,854股普通股。这些股票预计将以约1,153,982.45美元的总市值出售,作为限制性股票归属的一部分,于2024年4月18日被戈雷维奇收购,被视为发行人的补偿。该交易是在戈雷维奇在过去三个月中出售了53,755股普通股之后进行的,总收益为780,286.09美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息